First Horizon Names Jeffrey R. Balser, M.D., Ph.D. to its Board of Directors

First Horizon Corporation (FHN) has elected Jeffrey R. Balser, M.D., Ph.D., as an independent director to its board. Dr. Balser is the CEO and President of Vanderbilt University Medical Center, where he has led significant growth. The company highlights his leadership and financial expertise as valuable additions to their board.

Original reporting
Published Oct 27, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 12:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$FHN
Neutral
high confidence
Mentioned
$FHN
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$FHNNeutralLow
01

Why it matters

The board addition is a standard governance update with limited immediate market effect.

02

Market read

A routine board appointment with modest relevance for investors.

03

What to watch

Potential influence on risk management and community relations in the Southeast.

Relevance 5/10Novelty 5/10Timing: today

Background

First Horizon is a regional financial services firm based in Memphis, TN.

Company-level read

Ticker impact

$FHNNeutralHigh confidence
Context

First Horizon announced the election of Dr. Jeffrey R. Balser to its Board of Directors.

Expected impact

neutral

Evidence & confidence

Board changes are routine and typically do not move the stock unless tied to strategic shifts.

Market effects

None significant for the banking sector.

Limited to First Horizon's regional footprint.

Minimal

Counterpoint

The appointment could signal deeper strategic changes not yet disclosed.

Key entities

  • Jeffrey R. Balser, M.D., Ph.D.

    President and CEO of Vanderbilt University Medical Center, newly appointed independent director.

  • First Horizon Corporation

    Regional bank and financial services provider.

Related articles

$FHNMed

DA Davidson maintains First Horizon stock rating on loan sale strategy

DA Davidson reiterated a Neutral rating and $27.00 price target on First Horizon (FHN) after the bank announced plans to sell $4.5B in low-yielding mortgage loans, expecting a 4% EPS boost by 2027. FHN shares trade at $23.25, with a P/E ratio of 16.49 and a 2.97% dividend yield. The bank reported Q3 adjusted EPS of $0.53, beating estimates, and plans to resume share repurchases in Q4.

$FHNMedAI 8/10

First Horizon Corp (FHN) (Q3 2026) Earnings Call Highlights: Mortgage Portfolio Sale

First Horizon Corp reported Q3 2026 earnings with adjusted EPS declining to $0.53 due to lower fee income and higher provision expense. The company sold $4.5 billion in residential mortgage loans, expecting a 4% EPS accretion in 2027. Tangible book value per share fell 5% to $13.84. The mortgage sale aims to free up balance sheet capacity for higher-yielding loans and client relationships. Deposit costs increased 12 basis points to 2.45%, with competitive pressures expected to persist.

$FHNMedAI 8/10

First Horizon Corporation Q3 2026 Earnings Call Summary

First Horizon Corporation sold $4.5B in low-yielding mortgage loans at a 10% discount to boost profitability. The move aims to redeploy capital into higher-yielding loans, expecting a 4% EPS boost by 2027. Q3 saw $1.5B in client deposit growth, reducing reliance on expensive brokered deposits. Management plans to resume share buybacks in Q4 and targets a $100M+ PPNR opportunity.